drugset / Trial / NCT02269189

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

NCT02269189

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)

Timeline

Start
2002-04
Primary completion
2002-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 150 mg Oral
Subject AMELUBANT Small molecule 300 mg Oral

Indications